Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 3;7(1):1429.
doi: 10.1038/s41598-017-01588-5.

Risk of infections in patients with gout: a population-based cohort study

Affiliations

Risk of infections in patients with gout: a population-based cohort study

B Spaetgens et al. Sci Rep. .

Abstract

To investigate the risk of various types of infections (pneumonia and urinary tract infection (UTI)), and infection-related mortality in patients with gout compared with population-based controls. A retrospective cohort study was conducted using data from the UK Clinical Practice Research Datalink (CPRD). All patients with a first diagnosis of gout and aged >40 years between January 1987-July 2014, were included and matched with up to two controls. Time-varying Cox proportional hazards models were used to estimate the risk of infections and mortality. 131,565 patients and 252,763 controls (mean age: 64 years, 74% males, mean follow-up of 6.7 years) were included in the full cohort. After full statistical adjustment, the risk of pneumonia was increased (adj. HR 1.27, 95% CI 1.18 to 1.36), while the risk of UTI (adj. HR 0.99, 95% CI 0.97 to 1.01) was similar in patients compared to controls. No differences between patients and controls were observed for infection-related mortality due to pneumonia (adj. HR 1.03, 95% CI 0.93 to 1.14) or UTI (adj. HR 1.16, 95% CI 0.98 to 1.37). In conclusion, patients with gout did not have decreased risks of pneumonia, UTI or infection-related mortality compared to population-based controls.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flowchart of the study subjects.

Comment in

  • Bringt Gicht dem Immunsystem Power?
    Heppner HJ. Heppner HJ. MMW Fortschr Med. 2018 Feb;160(3):36. doi: 10.1007/s15006-018-0195-8. MMW Fortschr Med. 2018. PMID: 29464624 German. No abstract available.

Similar articles

Cited by

References

    1. Wijnands JM, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 2015;30:19–33. doi: 10.1007/s10654-014-9927-y. - DOI - PubMed
    1. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74:661–667. doi: 10.1136/annrheumdis-2013-204463. - DOI - PMC - PubMed
    1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–3141. doi: 10.1002/art.30520. - DOI - PubMed
    1. Richette P, Bardin T. Gout. Lancet. 2010;375:318–328. doi: 10.1016/S0140-6736(09)60883-7. - DOI - PubMed
    1. Robinson PC, Merriman TR, Herbison P, Highton J. Hospital admissions associated with gout and their comorbidities in New Zealand and England 1999–2009. Rheumatology (Oxford) 2013;52:118–126. doi: 10.1093/rheumatology/kes253. - DOI - PubMed